J. Qian

B. Han, Yu Dong, Xueyan Zhang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells

Y. Li, B. Han, Weifeng Mao, 2017, Yonsei medical journal.

Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.

Xiao-hong Fan, Yanwei Zhang, T. Chu, 2020, Lung cancer.

不同剂量紫杉醇联合卡铂一线治疗晚期非小细胞肺癌的临床研究

B. Han, H. Bai, Jie Shen, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.

B. Han, Y. Lou, Jianlin Xu, 2020, Clinical lung cancer.

Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma.

B. Han, C. Shi, J. Qian, 2017, International journal of clinical and experimental pathology.

Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.

B. Han, H. Zhong, C. Shi, 2016, Gene.

Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells

Liyan Jiang, J. Qian, S. Cui, 2018, Journal of Cancer.

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

B. Han, Jianlin Xu, Yanwei Zhang, 2020, Journal of Cancer Research and Clinical Oncology.

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

B. Han, Xueyan Zhang, Huimin Wang, 2020, Frontiers in Oncology.

JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

H. Zhong, C. Shi, T. Chu, 2019, Journal of Thoracic Oncology.

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Xueyan Zhang, H. Zhong, Jun Lu, 2022, Journal of Cancer Research and Clinical Oncology.

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

Liyan Jiang, L. Xiong, A. Gu, 2016, Cancer medicine.

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy

Juan Zhou, C. Su, F. Zhou, 2021, Translational lung cancer research.

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy

Xueyan Zhang, H. Zhong, Jun Lu, 2023, Clinical and translational medicine.

Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma

J. Qian, Chaoxian Zhao, Tianqing Chu, 2023, BMJ Open Respiratory Research.

Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma.

J. Qian, Tianqing Chu, Haijiao Lu, 2024, Chinese medical journal.